This discrepancy is particularly unfortunate, because not only do black Americans suffer disproportionately from many health conditions, they often experience illnesses differently and respond differently to medications, making race-specific trials even more crucial, the researchers noted.
"We're concerned that the lack of minority representation in clinical trials may perpetuate health disparities," Powell said.
Previous studies have shown that this under-representation is, in fact, due to individuals' unwillingness to participate, as opposed to researchers' exclusion of minorities.
And this unwillingness is widely thought to be due to the legacy of Tuskegee and other such research. The government-sponsored Tuskegee Study, named after a town in Alabama where participants were recruited, enrolled several hundred poor, black sharecroppers, telling them that they would receive drugs to treat their syphilis infections. But lifesaving drugs were purposely withheld so the "natural" course of the disease could be observed. The experiment was shut down after a leak to the press in 1972.
In this latest study, Powe and his colleagues conducted a random survey of 717 outpatients at 13 cardiology and general medicine clinics in Maryland. Thirty-six percent of participants were black, the rest white.
After an in-depth explanation by a physician (either black or white), each participant was asked to enroll in a mock trial of a cardiovascular drug.
Only 27 percent of black American respondents were willing to participate, versus 39 percent of whites.
Among the study's other findings:
| Copyright©2008 ScoutNews,LLC. All rights reserved |